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ZebraﬁshAdenosine, a purine ribonucleoside, exhibits neuromodulatory and neuroprotective effects in the brain
and is involved in memory formation and cognitive function. Adenosine signaling is mediated by aden-
osine receptors (A1, A2A, A2B, and A3); in turn, nucleotide and nucleoside-metabolizing enzymes and aden-
osine transporters regulate its levels. Scopolamine, a muscarinic cholinergic receptor antagonist, has
profound amnesic effects in a variety of learning paradigms and has been used to induce cognitive deﬁcits
in animal models. This study investigated the effects of acute exposure to caffeine (a non-selective antag-
onist of adenosine receptors A1 and A2A), ZM 241385 (adenosine receptor A2A antagonist), DPCPX (aden-
osine receptor A1 antagonist), dipyridamole (inhibitor of nucleoside transporters) and EHNA (inhibitor of
adenosine deaminase) in a model of pharmacological cognitive impairment induced by scopolamine in
adult zebraﬁsh. Caffeine, ZM 241385, DPCPX, dipyridamole, and EHNA were acutely administered inde-
pendently via i.p. in zebraﬁsh, followed by exposure to scopolamine dissolved in tank water (200 lM).
These compounds prevented the scopolamine-induced amnesia without impacting locomotor activity
or social interaction. Together, these data support the hypothesis that adenosine signaling may modulate
memory processing, suggesting that these compounds present a potential preventive strategy against
cognitive impairment.
 2014 Elsevier Inc. All rights reserved.1. Introduction
Alzheimer’s disease (AD) is a complex neurodegenerative dis-
order characterized by memory loss and cognitive deﬁcits
(Selkoe, 2001). AD etiology is not yet fully understood, though
hallmark neuropathological features have been identiﬁed and
include the deposition of senile plaques, neuroﬁbrillary tangles,
and progressive synaptic and neuronal loss (Haass & Selkoe,2007). Additionally, cholinergic transmission deﬁciencies have
been implicated in the cognitive decline observed in AD patients.
According to the cholinergic hypothesis, cognitive deterioration is
associated with a decrease in acetylcholine (ACh) levels due to its
rapid hydrolysis by acetylcholinesterase (AChE) (Bartus, Dean,
Beer, & Lippa, 1982). This hypothesis was the foundation for the
use of acetylcholinesterase inhibitors (AChEi) for the treatment
of cognitive deﬁcits in AD patients (Casey, Antimisiaris, &
O´Brien, 2010; Small, 2005).
Scopolamine, a muscarinic cholinergic receptor antagonist, is
known to impair learning and memory formation and used to
model cognitive deﬁcits in animal models (Klinkenberg &
Blokland, 2010). The zebraﬁsh, a small tropical freshwater teleost,
has emerged as a prominent animal model for studying complex
behaviors including learning and memory. Several memory tasks
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the plus maze, Y-maze, and inhibitory avoidance task, which have
proven to be useful tools for evaluating several behavioral and
pharmacological conditions in this species (Blank, Guerim,
Cordeiro, & Vianna, 2009; Cognato et al., 2012; Sison & Gerlai,
2010). The high genomic similarity to humans (Howe et al.,
2013) and the identiﬁcation of classical neurotransmitter systems
involved in learning and memory processing, such as glutamater-
gic (Todd, Slatter, & Ali, 2004) and cholinergic (Clemente et al.,
2004) systems, are important aspects for modeling neurological
disorders in zebraﬁsh (Best & Alderton, 2008; Stewart, Braubach,
Spitsbergen, Gerlai, & Kalueff, 2014). Previous studies have demon-
strated that scopolamine induces cognitive impairment and dis-
rupts aversive and recognition memory processing in zebraﬁsh
(Cognato et al., 2012; Kim, Lee, Kim, Jung, & Lee, 2010; Richetti
et al., 2011).
Adenosine, a purine ribonucleoside, plays important roles as a
homeostatic regulator and neuromodulator, controlling neuronal
excitability and, consequently, modulating physiological and path-
ological conditions of the central nervous system (CNS) (Boison,
2012; Chen, Eltzschig, & Fredholm, 2013; Dias, Rombo, Ribeiro,
Henley, & Sebastião, 2013). Adenosine signaling is mediated via
four G-protein coupled receptors: A1, A2A, A2B, and A3. These recep-
tors were identiﬁed in several species including zebraﬁsh
(Boehmler et al., 2009; Capiotti et al., 2011) and are linked to a
variety of transduction mechanisms (Fredholm, IJzerman,
Jacobson, Linden, & Müller, 2011). Extracellular adenosine levels
are dynamically controlled by the action of ectonucleotidases,
involved in adenosine production by ATP degradation and equili-
brative and concentrative nucleoside transporters (Bonan, 2012).
In addition, adenosine may be deaminated by adenosine deami-
nase (ADA), a mainly cytosolic enzyme that is also found in the
external cell surface already described in zebraﬁsh (Rosemberg
et al., 2007).
The involvement of adenosine receptors in cognitive processes
in humans and rodents has been demonstrated (Gomes, Kaster,
Tomé, Agostinho, & Cunha, 2011; Sebastiao, Ribeiro, & Ribeiro,
2012). Post-mortem analysis of frontal cortex from AD patients
revealed a signiﬁcant increase in A1 and A2A receptor expression
in early and advanced stages of disease (Albasanz, Perez,
Barrachina, Ferrer, & Martín, 2008). Epidemiological studies dem-
onstrated that the incidence of AD was inversely associated with
consumption of caffeine, which acts as a non-selective adenosine
receptor antagonist (Maia & De Mendonça, 2002; Ritchie et al.,
2007). Caffeine also prevented the scopolamine-induced disrup-
tion of short- and long-term memory in rodents and humans
(Botton et al., 2010; Riedel et al., 1995). Studies using the A1 and
A2A dual antagonist ASP5854 exhibited reversion of scopolamine-
induced memory deﬁcits in rats, whereas the speciﬁc A2A
antagonist KW-6002 had no such effect. Similarly, selective A2A
antagonist SCH58261 failed to reverse either MK-801- or scopol-
amine-induced amnesia in rats (Cunha et al., 2008). This evidence
supports the speciﬁc involvement of A1 receptor antagonism in
cognition (Mihara et al., 2007).
Therefore, considering: (i) the role of adenosine receptors in
prevention or reversion of scopolamine-induced memory deﬁcits,
(ii) the relevance of zebraﬁsh as a powerful model for modeling
neurological disorders and pharmacological studies and, (iii) the
modulation of adenosine signaling exerted by nucleotide and
nucleoside-metabolizing enzymes and adenosine transporters, this
study aimed to investigate the effects of acute administration of
caffeine, ZM 241385 (adenosine A2A receptor antagonist), DPCPX
(adenosine A1 receptor antagonist), dipyridamole (inhibitor of
nucleoside transporters) and EHNA (inhibitor of adenosine deami-
nase) in a model of pharmacological cognitive impairment induced
by scopolamine in adult zebraﬁsh.2. Materials and methods
2.1. Animals
Adult wild type zebraﬁsh (0.3–0.5 g) were obtained from a spe-
cialized supplier (Redﬁsh Agroloja, RS, Brazil). Animals were kept
in 30-L housing tanks with unchlorinated water at a targeted tem-
perature of 26 ± 2 C and continuously aerated under 14:10 h
light:dark photoperiod. The ﬁsh were acclimated to the laboratory
environment for at least 14 days and were fed three times a day
with commercial ﬂake food supplemented with brine shrimp. All
procedures were approved by the institutional Animal Care
Committee (11/00257-CEUA-PUCRS).2.2. Pharmacological treatments
Caffeine (1,3,7-trimethylxanthine; Sigma Chemical Co., USA),
ZM 241385 (4-(2-[7-amino-2-{2-furyl}{1,2,4}triazolo-{2,3-
a}{1,3,5}triazin-5-yl-amino]ethyl) phenol; Tocris Cookson, USA),
DPCPX (8-cyclopentyl-1,3-dipropylxanthine; Tocris Cookson,
USA), EHNA (erythro-9-(2-hydroxy-3-nonyl)-adenine hydrochlo-
ride; Sigma–Aldrich, St Louis, MO) and dipyridamole (Sigma–
Aldrich, St Louis, MO) were used in the study. Caffeine and EHNA
were dissolved in saline (0.9% NaCl); ZM 241385, DPCPX and dipy-
ridamole were dissolved in 1% DMSO (dimethylsulfoxide). Caffeine
(10 mg/kg), ZM 241385 (10 lg/kg), DPCPX (0.5 mg/kg), dipyridam-
ole (5 mg/kg), and EHNA (100 lg/kg) were administered via intra-
peritoneal (i.p.) injection in a volume of 10 lL using a 3/10-mL
U100 BD Ultra-Fine™ Short Insulin Syringe 8 mm (5/16’’)  31G
Short Needle (Becton Dickinson and Company, New Jersey, USA)
(Kinkel, Eames, Philipson, & Prince, 2010). Drug doses and admin-
istration routes were chosen and adjusted based on previous stud-
ies demonstrating effects on memory in rodents (Melani, Cipriani,
Corti, & Pedata, 2010; Prediger & Takahashi, 2005). Only doses that
were unable to alter locomotor activity were used to ensure the
effects observed were related to memory processing. Before drug
or vehicle administration, ﬁsh were anesthetized by immersion
in 0.1 g/L tricaine solution (ethyl 3-aminobenzoate methanesulfo-
nate salt; Fluka, Buchs, Switzerland).
After treatment, animals were placed in a separate tank with
aerated, unchlorinated tap water to recover from the anesthesia.
Caffeine, ZM 241385, DPCPX, dipyridamole, EHNA, and the appro-
priate vehicle (used as control group) were injected 2 h before the
beginning of each experiment. One hour prior to the start of the
behavioral assay, animals were transferred to a tank containing
200 lM scopolamine solution (dissolved in aerated, unchlorinated
water). Animals that did not receive scopolamine were also trans-
ferred to another tank with water to control for handling effects
(Kim et al., 2010).2.3. Behavioral analysis
2.3.1. Inhibitory avoidance task
Long-term memory was evaluated using the inhibitory avoid-
ance (IA) protocol previously described in detail (Blank et al.,
2009). After treatment, zebraﬁsh were individually trained and
tested in a glass tank (18 cm L  9 cm H  7 cmW) divided by a
sliding guillotine-type partition (9 cm  7 cm) in two equally sized
compartments, white and dark. During a training session, animals
were individually placed in the white side of the tank with the par-
tition closed. After 1 min of habituation, the partition was raised
1 cm, allowing ﬁsh to cross to the dark side of the tank. Immedi-
ately after crossing and entering the dark side, the slide partition
was closed and a pulsed electric shock of 3 ± 0.2 V was adminis-
tered for 5 s. Fish were then removed from the apparatus and
Fig. 1. Pretreatment with adenosine receptor antagonists caffeine (CAF), ZM
241385 (ZM), and DPCPX (DP) prevented scopolamine-induced memory impair-
ment in the inhibitory avoidance task. Animals received a single i.p. injection of
saline (S), DMSO (D), caffeine (10 mg/kg), ZM 241385 (10 lg/kg) or DPCPX (0.5 mg/
kg) 2 h before the training session. The i.p. treatment was followed by a 1 h
exposure to water or scopolamine prior to testing. Effects of scopolamine or water
on the latency to enter the dark compartment during training and test sessions in
the inhibitory avoidance task were evaluated. Data are presented as mean ± SEM
(n = 12 per group) ⁄p < 0.05 ⁄⁄p < 0.001 ⁄⁄⁄p < 0.0001 indicate differences between
training and test session for each group compared by Wilcoxon matched pair test.
No differences were found between training performances among all groups as
evaluated by Kruskal–Wallis test.
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ing tank. Twenty-four hours after a training session, animals were
submitted to a test session. The test session repeated the training
protocol except that no shock was administered. The latency to
completely enter the dark compartment was measured during
both sessions.
2.3.2. Exploratory assessment
After animals received the second treatment, they were placed
individually in the experimental tanks (30 cm L  15 cm H 
10 cmW) and habituated for 30 s, as previously described
(Gerlai, Lahav, Guo, & Rosenthal, 2000). After the habituation per-
iod, locomotor activity was video recorded for 5 min using Logitech
Quickcam PRO 9000 and quantitatively analyzed using ANY-Maze
recording software (Stoelting Co. Wood Dale, IL, USA). The tank
was virtually divided into equal sections with three vertical lines
and one horizontal line. The behavioral patterns quantiﬁed were
the number of sectional line crossings, distance traveled, mean
speed, and time spent in each tank section (i.e., the bottom vs.
upper levels). Because zebraﬁsh have a natural tendency to spend
more time at the bottom of a novel tank before gradually exploring
higher portions of the tank over a period of minutes, time spent in
each tank section can be used as a measure of anxiety (Levin,
Bencan, & Cerutti, 2007). All exploratory assessment was per-
formed between 9:00 a.m. and 1:00 p.m.
2.3.3. Social interaction
The zebraﬁsh is a social animal. To test social interaction,
animals from the same shoal were used in each experiment. Five
experimental ﬁsh were placed in a small experimental aquarium
(30 cm L  15 cm H  10 cmW). On one side of the experimental
aquarium, an empty tank was placed; on the opposing side, a
‘‘stimulus tank’’ of identical size held 15 zebraﬁsh. The behavior
of experimental ﬁsh was recorded after 30 s of habituation time.
In order to quantify any inherent preference for the ‘‘stimulus’’
side, the central tank was in two equal parts; the time that exper-
imental ﬁsh spent in the virtual half adjacent to the conspeciﬁc
school was measured (Gerlai, 2003).
2.4. Statistical analysis
Inhibitory avoidance memory data are presented as mean ±
S.E.M. Training and test latencies for each group were compared
by Wilcoxon matched pairs test. Latencies of multiple groups were
compared using Kruskal–Wallis and Mann–Whitney U tests.
Exploratory assessment and social interaction data were analyzed
via one-way analysis of variance (ANOVA) followed by post hoc
comparisons using Tukey’s HSD test and were expressed as the
mean ± S.E.M. For all comparisons, p < 0.05 was considered
signiﬁcant.3. Results
3.1. Caffeine, ZM 241385, DPCPX, dipyridamole, and EHNA prevent
scopolamine-induced memory deﬁcits
We ﬁrst analyzed the inﬂuence of pretreatment with adenosine
receptor antagonists on scopolamine-inducedmemory impairment
using an inhibitory avoidance task. We independently evaluated
the effects of caffeine (10 mg/kg), ZM 241385 (10 lg/kg), and
DPCPX (0.5 mg/kg) i.p treatment, followed by pre-training scopol-
amine (200 lM) exposure (Fig. 1). Saline was used as vehicle for
caffeine and 1% DMSO was used as vehicle for both ZM 241385
and DPCPX. Vehicle-exposed animals followed by water treatment
demonstrated robust retention of memory during the test sessionperformed 24 h after training (p < 0.05). Pretreatment of caffeine
(p < 0.001), ZM 241385 (p < 0.05) or DPCPX (p < 0.001), followed
by water treatment, resulted in signiﬁcant differences between
zebraﬁsh training and test sessions, thus suggesting effective learn-
ing of the task. However, vehicle-exposed animals subsequently
treated with scopolamine did not exhibit memory retention during
the test session performed 24 h after training. Interestingly, treat-
ment with either caffeine, ZM 241385 or DPCPX prevented the
memory impairment induced by pre-training scopolamine expo-
sure, as observed by the difference in latencies between training
and test sessions for each treatment (p < 0.0001, p < 0.001, and
p < 0.0001, respectively) (Fig. 1). In addition, there were no signiﬁ-
cant differences in the latencies for test sessions between the
groups pretreated with adenosine receptor antagonists (Caffeine,
ZM241385, or DPCPX) followed bywater or scopolamine treatment.
These results suggest that adenosine A1 and A2A receptor antago-
nists ameliorated scopolamine-induced memory impairment.
To elucidate the roles of nucleoside transporters and nucleo-
side-metabolizing enzymes in scopolamine-induced memory deﬁ-
cit, respectively, we tested an inhibitor of nucleoside transporters,
dipyridamole, and an inhibitor of adenosine deaminase, EHNA
(Fig. 2). Animals treated with 1% DMSO or dipyridamole (5 mg/
kg) followed by water exposure presented robust memory reten-
tion, exhibiting signiﬁcant differences between their training and
test sessions (p < 0.05 for each group analyzed separately)
(Fig. 2A). However, pre-training scopolamine exposure disrupted
memory formation in 1% DMSO-treated animals. In contrast, dipy-
ridamole prevented scopolamine-induced impairment, as evident
in the signiﬁcant difference between training and test session
latencies (p < 0.05) (Fig. 2A). Similarly, pretreatment with EHNA
prevented scopolamine-induced memory deﬁcits (p < 0.001;
Fig. 2B). Taken together, these results suggest that acute treatment
of either dipyridamole or EHNA before scopolamine treatment pre-
vents the reliably induced memory impairment that would follow.3.2. Effects of scopolamine and purinergic modulation on exploratory
assessment
Zebraﬁsh exploratory activity was evaluated after i.p. injections
of caffeine, ZM 241385, DPCPX, dipyridamole, and EHNA, com-
bined with subsequent water or scopolamine treatment. No signif-
icant difference in either distance travelled or mean speed were
found in animals that received any of the treatments when
Fig. 2. Pretreatment with dipyridamole (DIPI) or EHNA prevented scopolamine-induced memory impairment during the inhibitory avoidance task. (A) Animals received a
single i.p. injection of DMSO (D) or DIPI (5 mg/kg). (B) Animals received a single i.p. injection of saline (S) or EHNA (100 lg/kg). The i.p. treatment, administered 2 h before the
training sessions, was followed by a 1 h exposure of either water or scopolamine prior to testing. The effects of scopolamine and water on the latency to enter the dark
compartment in training and test sessions in the inhibitory avoidance task were evaluated. Data are presented as mean ± S.E.M (n = 12 per group); ⁄p < 0.05 ⁄⁄p < 0.001
indicate the differences between training and test sessions for each group compared via Wilcoxon matched pair test. No differences were found between training
performance among all groups as evaluated by Kruskal–Wallis test.
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Swimming coordination was also evaluated; none of the treat-
ments altered the absolute body turn angle during swimming
(Figs. 3C and 4C). Time spent in the upper and lower portions of
the tank was measured to evaluate anxiety; no signiﬁcant differ-
ences were found in treated animals when compared to their
respective control group (saline or 1% DMSO; Figs. 3D and E and
4D and E).
3.3. Effects of scopolamine, caffeine, ZM 241385, DPCPX, dipyridamole,
and EHNA on social interaction
Social interaction was evaluated after i.p. injections of caffeine,
ZM 241385, DPCPX, dipyridamole, and EHNA, followed by water or
scopolamine (Fig. 5A and B). There were no signiﬁcant changes
between experimental groups in the time spent near the stimulus
tank, indicating that social interaction was not altered by either
scopolamine or modulators of adenosine signaling.Fig. 3. Locomotor activity was evaluated after an i.p. injection of adenosine receptor anta
water (W) exposure. Metrics measured include distance traveled (A), mean speed (B), ab
(E). No differences were found between groups. Data are expressed as mean ± S.E.M. of 1
saline + water; SS, saline + scopolamine; DW, DMSO + water; DS, DMSO + scopolamine;
ZMS, ZM 241385 + scopolamine; DPW, DPCPX + water; DPS, DPCPX + scopolamine.4. Discussion
In this study, we evaluated the preventive role of adenosine sig-
naling modulation on scopolamine-induced memory deﬁcits in
zebraﬁsh. Previous studies using adult zebraﬁsh showed that sco-
polamine triggered robust impairment of memory during an inhib-
itory avoidance task (Kim et al., 2010; Richetti et al., 2011). Our
data demonstrated that acute i.p pretreatments with non-selective
adenosine receptor antagonist caffeine, and the selective antago-
nists of A2A (ZM 241385) and A1 (DPCPX) receptors all prevented
the scopolamine-induced memory deﬁcits observed in the inhibi-
tory avoidance task. This study also demonstrates that the inhibi-
tion of either nucleoside transporters or nucleoside-metabolizing
enzyme adenosine deaminase using dipyridamole and EHNA,
respectively, prevents scopolamine-induced memory impairment.
Studies have also demonstrated the prevention of scopolamine-
induced cognitive impairment in mice using acute pretreatment
with caffeine (10 mg/kg) (Botton et al., 2010). Other studiesgonist caffeine (CAF), ZM 241385 (ZM) or DPCPX (DP) followed by scopolamine (S) or
solute turn angle (C), time spent in upper zone (D), and time spent in lower zone in
2 different animals for each group and were analyzed by one-way ANOVA test. SW,
CAFW, caffeine + water; CAFS, caffeine + scopolamine; ZMW, ZM 241385 + water;
Fig. 4. Locomotor activity was evaluated after an i.p. injection of dipyridamole (DI) or EHNA (EH), followed by scopolamine (S) or water (W) exposure. Analyzed metrics
include distance traveled (A), mean speed (B), absolute turn angle (C), time spent in upper zone (D), and time spent in lower zone in (E). No differences were found between
groups. Data are expressed as mean ± S.E.M. of 12 different animals for each group and were analyzed by one-way ANOVA test. SW, saline + water; SS, saline + scopolamine;
DW, DMSO + water; DS, DMSO + scopolamine; DIW, dipyridamole + water; DIS, dipyridamole + scopolamine; EHW, EHNA + water; EHS, EHNA + scopolamine.
Fig. 5. Social interaction was evaluated after the i.p. injection of adenosine receptor antagonist caffeine (CAF), ZM 241385 (ZM), DPCPX (DP; A) or dipyridamole (DI), EHNA
(EH; B), followed by scopolamine or water treatment. Saline (S) or saline plus DMSO (D) was used as a control. No differences were found between groups. Data are expressed
as mean ± S.E.M. of 6 different groups and were analyzed via one-way ANOVA.
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to memory deﬁcits induced by a variety of factors such as alcohol
(Spinetta et al., 2008) and beta-amyloid (Dall’Igna et al., 2007). Fur-
thermore, chronic intake of caffeine in a transgenic mouse model
of AD improved cognition in mice (Arendash et al., 2006) and
reduced the deposition of senile plaques (Arendash et al., 2009;
Cao et al., 2009). Short and long-term memories formed during
an inhibitory avoidance task were improved in middle-aged mice
chronically treated with caffeine (Sallaberry et al., 2013). In
humans, a placebo-controlled blind crossover study showed that
three cups of coffee per day attenuated the scopolamine-induced
impairment of several parameters in a word learning task, includ-
ing free recall from short- and long-term memory, retrieval quality
and speed (Riedel et al., 1995). Other studies performed in humans
corroborate the potential of caffeine with respect to reducing cog-
nitive decline (Ritchie et al., 2007; van Gelder et al., 2007). Our
results are in agreement with previous studies, demonstrating that
acute caffeine treatment prevents the memory disruption caused
by scopolamine in zebraﬁsh.
The psychostimulant effect of caffeine on the central nervous
system (CNS) is primarily due to the antagonism of adenosine
receptors A1 and A2A (Ferré, 2008; Fredholm, Bättig, Holmén,
Nehlig, & Zvartau, 1999). We have shown that selective antago-
nism of adenosine A2A or A1 receptors by ZM 241385 and DPCPX,respectively, prevented scopolamine-induced memory deﬁcits
during an inhibitory avoidance task in zebraﬁsh. Other studies
have also described the beneﬁcial effects of A2A antagonism on
the synaptic mechanisms of learning and memory in AD animal
models and patients (Cunha & Agostinho, 2010; Takahashi,
Pamplona, & Prediger, 2008). Rats overexpressing A2A receptors
presented memory deﬁcits (Giménez-Llort et al., 2007), while mice
lacking adenosine A2A receptors have improved spatial recognition
memory (Wang, Ma, & van den Buuse, 2006). Interestingly, the A2A
receptor antagonist SCH5861 was unable to prevent the memory
deﬁcits induced by scopolamine treatment in rats during a Y-maze
task (Cunha et al., 2008). The discrepancies between our work and
this result can be attributed to the different memory tasks
employed and/or the different methods of scopolamine adminis-
tration. In addition, we did not observe alterations in locomotion
after scopolamine treatment, which differs from the results
observed by Cunha et al. (2008). Our results suggest that A2A antag-
onism can improve memory performance without changes in loco-
motor activity.
Our results demonstrated that blockade of adenosine A1 recep-
tor by DPCPX prevents scopolamine-induced memory impairment
in zebraﬁsh. Accordingly, previous work demonstrated signiﬁcant
improvement of scopolamine-induced memory impairment using
DPCPX in mice (Zhang & Ren, 2003). Another study characterized
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avoidance memory. FR194921 ameliorated scopolamine-induced
memory deﬁcits in rats, suggesting this compound harbors a
potential for cognitive enhancement (Maemoto et al., 2004). Simi-
lar results were observed by Pitsikas and Borsini (1997) using an
antagonist of A1 receptors, BIIP 20, which restored the memory
deﬁcits caused by scopolamine in rats (Pitsikas & Borsini, 1997).
To better understand the role of adenosine signaling in memory
impairment, we tested the effects of inhibitors of nucleoside trans-
port (dipyridamole) and adenosine deamination (EHNA) on scopol-
amine-induced memory deﬁcits in zebraﬁsh. Nucleoside
transporters were acutely blocked with dipyridamole, resulting
in a signiﬁcant improvement in scopolamine-induced memory
impairment. Dipyridamole was previously used in a model of vas-
cular cognitive impairment in rats caused by bilateral carotid
artery occlusion (Melani et al., 2010). After one week of intrave-
nous perfusion, it signiﬁcantly restored spatial memory in the
Y-maze test. Dipyridamole is commonly used to inhibit platelet
aggregation and reduce thrombi formation in vivo (Heptinstall,
Fox, Crawford, & Hawkins, 1986). However, few investigations
have demonstrated any neuroprotective properties of this com-
pound in vivo. In vitro studies, however, have revealed a neuropro-
tective effect of dipyridamole in neuronal cultures, most likely due
to its role as an antioxidant (Blake, 2004; Farinelli, Greene, &
Friedman, 1998). More recently, studies have suggested that dipy-
ridamole can augment vessel function, restoring blood ﬂow in
cerebrovascular disease (Chakrabarti & Freedman, 2008). In blood
cells, the antiplatelet mechanism of dipyridamole is due in part
to the inhibition of adenosine uptake. The increased extracellular
concentration of adenosine results in vasodilation (Geiger, 2001).
As adenosine is known for its neuroprotective role in the CNS, it
is possible that dipyridamole acts by controlling nucleoside levels
and, consequently, inducing an improvement in scopolamine-
induced memory deﬁcits in zebraﬁsh.
Adenosine deaminase catalyzes the irreversible deamination of
adenosine to inosine (Franco et al., 1997). A previous study demon-
strated that scopolamine increased adenosine deaminase activity
in rat cerebral cortex and hippocampus synaptosomes. However,
adenosine levels measured by HPLC did not change upon scopol-
amine treatment (Gutierres et al., 2012). Our results demonstrate
that acute pretreatment with EHNA, an ADA inhibitor, protected
zebraﬁsh from the memory impairment caused by scopolamine.
Adenosine has been reported as a neuromodulator, with an impor-
tant role in synaptic plasticity and memory processing, and its
depletion can disrupt memory formation (de Mendonça,
Costenla, & Ribeiro, 2002; de Mendonça & Ribeiro, 1997). The data
presented here suggests that modulation of adenosine levels via
the inhibition of nucleoside transporters or adenosine metabolism
can prevent scopolamine-induced effects, reinforcing the proposed
involvement of adenosine signaling in cognitive function.
Scopolamine is a classical model of induced amnesia. However,
some studies have been questioned the use of scopolamine for
inducing cognitive impairment due to differences in data related
to locomotor analyses (Klinkenberg & Blokland, 2010). As shown
in Figs. 3 and 4, we did not observe changes in locomotor param-
eters between control and treated ﬁsh. In addition, there were no
changes in the time spent in the upper or lower portions of the
tank, suggesting that scopolamine did not alter anxiety parameters
in zebraﬁsh. These data are in agreement with previous studies in
both zebraﬁsh and rodents (Botton et al., 2010; Gutierres et al.,
2012; Kim et al., 2010; Richetti et al., 2011). However, Cunha and
coworkers (2008) observed scopolamine-induced hyperlocomo-
tion that was not prevented by SCH58261 (Cunha et al., 2008).
Zebraﬁsh are a social species and they prefer to swim in groups
(Engeszer, Patterson, Rao, & Parichy, 2007; Miller & Gerlai, 2007).
Evidence suggests that the cholinergic system participates in socialrecognition (Wang, Karp, Winblad, & Fratiglioni, 2002; Winslow &
Camacho, 1995). Our data revealed no changes in social interaction
between the control and treated groups (Fig. 5). In mice, social
interaction was not altered by different doses of scopolamine;
however, social memory was impaired by scopolamine in a dose-
dependent manner (Riedel, Kang, Choi, & Platt, 2009). These results
suggest that scopolamine promotes memory disruption without
changes in social interaction.
5. Conclusion
In conclusion, our results support the idea that the antagonism
of adenosine receptors or a possible increase of adenosine levels
induced by inhibition of nucleoside transport or adenosine catabo-
lism prevented scopolamine-induced memory deﬁcits. This data
corroborates the hypothesis that adenosine signaling is involved
in memory processing in zebraﬁsh and may be a target for
the development of preventive strategies against cognitive
impairment.
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